---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-002847"
form_type: "8-K"
ticker: "ICU"
cik: "0001831868"
company_name: "SeaStar Medical Holding Corp"
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:46:30.362323+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# SeaStar Medical reports 5,997,246 shares outstanding; updates on clinical and commercial progress

## Summary
- As of Dec 31, 2024, common shares outstanding: 5,997,246 (Jan 8, 2025: 5,977,246).
- QUELIMMUNE (SCD-PED) FDA-approved Feb 2024; first commercial shipment July 2024; 4 hospital customers as of Q1 2025.
- NEUTRALIZE-AKI adult pivotal trial 37% enrolled (74 of 200 subjects); 14 of 30 sites activated; CMS covers trial costs.
- Four FDA Breakthrough Device Designations: adult AKI, cardiorenal syndrome w/ LVAD, hepatorenal syndrome, chronic dialysis.
- Zero interest-bearing debt; cash use $11.3M YTD through Q3 2024; raised ~$20M new equity through Q3 2024.

## SEC filing metadata
- accession: 0001213900-25-002847
- form_type: 8-K
- ticker: ICU
- cik: 0001831868
- company_name: SeaStar Medical Holding Corp
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831868/000121390025002847/0001213900-25-002847-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831868/000121390025002847/ea0227427-8k_seastar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-002847
- JSON: https://secwatch.observer/filing/0001213900-25-002847.json
- Plain text: https://secwatch.observer/filing/0001213900-25-002847.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.